The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors.
 
Daneng Li
Consulting or Advisory Role - Abbvie; AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences; TriSalus Life Sciences
Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst)
 
Amanda Seiz
Employment - Imugene
Stock and Other Ownership Interests - Imugene
 
Seymour H. Fein
Employment - Imugene
 
John Chong Han Byon
Employment - Imugene; Seagen (I)
Stock and Other Ownership Interests - Fate Therapeutics; Imugene; Seagen (I)
Consulting or Advisory Role - CARGO Therapeutics
Travel, Accommodations, Expenses - Fate Therapeutics; Imugene; Seagen (I)
 
Grey A Wilkinson
Employment - Imugene
Stock and Other Ownership Interests - Imugene
 
Paul Paul Woodard
Employment - Immune-Onc Therapeutics; Imugene
Leadership - Immune-Onc Therapeutics; Imugene
Stock and Other Ownership Interests - Immune-Onc Therapeutics
Patents, Royalties, Other Intellectual Property - 1. Patent application for use of atezolizumab + talimogene lahereparepvec in triple negative breast cancer.
Travel, Accommodations, Expenses - Immune-Onc Therapeutics; Imugene